Margarida Maia, PhD, science writer —

Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and adjustment, but helps to safely prevent swelling episodes in hereditary angioedema (HAE) patients. That’s according to a study reporting the process of such a treatment transition for four family members…

Switching to Orladeyo (berotralstat) may help reduce the frequency and duration of swelling attacks in people with hereditary angioedema (HAE) who have normal levels and activity of a protein called C1-inhibitor, according to a European case series. These data add “clinically relevant evidence” to a growing body of…

An immediate-release capsule of deucrictibant that’s being developed by Pharvaris continues to show promise as an on-demand and preventive treatment for attacks of hereditary angioedema (HAE). “We believe deucrictibant is the only oral molecule with the potential to address both the on-demand and prophylactic treatment modalities for people…

A young woman who developed angioedema of the small bowel after taking two different angiotensin-converting enzyme (ACE) inhibitors showed elevated D-dimer blood levels, according to a pair of researchers in China. Stopping the medication quickly eased her angioedema symptoms. Her D-dimer levels dropped to normal, too, leading researchers…

A man in Japan may have developed acquired angioedema as a late complication of graft-versus-host disease, which occurred when stem cells from a cord blood transplant he received to treat cancer turned against his own body, according to a recent report. A diagnosis was made based on a…

People with hereditary angioedema (HAE) who were new to Orladeyo (berotralstat) treatment saw rapid reductions in the number of swelling attacks they experienced soon after starting the oral therapy, according to real-world data from the U.S. The benefits of Orladeyo lasted as long as 18 months, or about…

Sebetralstat, an oral small molecule being developed by KalVista Pharmaceuticals as an on-demand treatment for hereditary angioedema (HAE), has been issued an innovation passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). An innovation passport is the first step into the U.K.’s Innovative Licensing and Access…

Three genetic regions were found to be associated with the risk of developing angioedema as a side effect of angiotensin-converting enzyme (ACE) inhibitors, according to a genome-wide association study (GWAS) of European and African-American people. These include a new genetic locus that hadn’t been…

People with hereditary angioedema (HAE) who switched from long-term androgen treatment to BioCryst Pharmaceuticals’ Orladeyo (berotralstat) saw a reduction in the number of swelling attacks. That’s according to a new analysis of data from patients who discontinued androgens less than 60 days (two months) before entering APeX-S…

Argentina’s regulatory body has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) to prevent swelling attacks in adults and adolescents, ages 12 and older, who have hereditary angioedema (HAE). The decision by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) comes a few months after the approval of…